When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Webb took on several high-profile public roles in Hong Kong to champion the interest of shareholders and investors, including ...

A new study by UC San Francisco found that prostate cancer cases are increasing in California, likely due to a change in ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...